Browsing by Author "Kumar, V"

Now showing 1 - 5 of 5

Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase
(Elsevier, 2019) Kumar, Bhupinder; Kumar, V; Prashar, V; Saini, S; Dwivedi, A.R; Bajaj, B; Mehta, D; Parkash, Jyoti; Kumar, Vinod
Alzheimer's disease (AD) is a multifactorial neurological disorder involving complex pathogenesis. Single target directed drugs proved ineffective and since last few years' different pharmacological strategies including multi-targeting agents are being explored for the effective drug development for AD. A total of 19 dipropargyl substituted diphenylpyrimidines have been synthesized and evaluated for the monoamine oxidase (MAO) and acetylcholinesterase (AChE) inhibition potential. All the compounds were found to be selective and reversible inhibitors of MAO-B isoform. These compounds also displayed good AChE inhibition potential with IC50 values in low micromolar range. AVB4 was found to be the most potent MAO-B inhibitor with IC50 value of 1.49 ± 0.09 μM and AVB1 was found to be the most potent AChE inhibitor with IC50 value of 1.35 ± 0.03 μM. In the ROS protection inhibition studies, AVB1 and AVB4 displayed weak but interesting activity in SH-SY5Y cells. In the cytotoxicity studies involving SH-SY5Y cells, both AVB1 and AVB4 were found to be non-toxic to the tissue cells. In the molecular dynamic simulation studies of 30 ns, the potent compounds were found to be quite stable in the active site of MAO-B and AChE. The results suggested that AVB1 and AVB4 are promising dual inhibitors and have the potential to be developed as anti-Alzheimer's drug. © 2019
Drug-metabolizing enzymes: role in drug resistance in cancer
(Springer, 2020) Kaur, G; Gupta, S.K; Singh, P; Ali, V; Kumar, V; Verma, M.
Although continuous researches are going on for the discovery of new chemotherapeutic agents, resistance to these anticancer agents has made it really difficult to reach the fruitful results. There are many causes for this resistance that are being studied by the researchers across the world, but still, success is far because there are several factors that are going along unattended or have been studied less. Drug-metabolizing enzymes (DMEs) are one of these factors, on which less study has been conducted. DMEs include Phase I and Phase II enzymes. Cytochrome P450s (CYPs) are major Phase I enzymes while glutathione-S-transferases (GSTs), UDP-glucuronosyltransferases (UGTs), dihydropyrimidine dehydrogenases are the major enzymes belonging to the Phase II enzymes. These enzymes play an important role in detoxification of the xenobiotics as well as the metabolism of drugs, depending upon the tissue in which they are expressed. When present in tumorous tissues, they cause resistance by metabolizing the drugs and rendering them inactive. In this review, the role of these various enzymes in anticancer drug metabolism and the possibilities for overcoming the resistance have been discussed. � 2020, Federaci�n de Sociedades Espa�olas de Oncolog�a (FESEO).
Recent advances in decarboxylative C-C bond formation using direct or in situ generated alkenyl acids
(Taylor and Francis Inc., 2020) Kaur, P; Kumar, V; Kumar, R.
In recent years, the reactions of abundantly available, inexpensive, and structurally diverse alkenyl acids (-C=C-COOH) with C-X (X�=�halogen) or C-H coupling partner have emerged as vital strategies for the streamlined synthesis of functionalized alkenes with extrusion of innocuous CO2. Various alkenyl acids such as cinnamic acids can act as stable surrogates for the polymerization prone styrenes/olefins, which otherwise need special attention for their handling and storage. Furthermore, cinnamic acids can be easily prepared through various methodologies including Knoevenagel-Doebner (KD) condensation, Heck coupling reaction, etc. Recently, various one-pot tandem methodologies involving the decarboxylative coupling of KD/Heck sequence with C-H or C-X substrate have come into fore. The present review article edifies about the recent advances, scope and limitations for C-C bond formation via (i) direct decarboxylative functionalization of C-X or C-H substrate with alkenyl acids, (ii) tandem one-pot multicomponent decarboxylative approaches (involving in situ generated alkenyl acids) e.g. coupling of KD/Heck sequences with C-X or C-H substrate. � 2019, � 2019 Taylor & Francis.
A study of mechanistic mapping of novel SNPs to male breast cancer
(Humana Press Inc., 2019) Kaur, R.P; Kumar, V; Shafi, G; Vashistha, R; Kulharia, Mahesh; Munshi, Aanjan
Alterations in BRCA2, PALB2, CHEK2, and p53 genes have been identified for their association with male breast cancer in various studies. The incidence of male breast cancer in India is consistent with its global rate. The present study was carried out with an aim to evaluate the genetic alterations in male breast cancer patients from Malwa region of Punjab, India. Four male breast cancer patients belonging to different families were recruited from Guru Gobind Singh Medical College and Hospital, Faridkot, India. A total of 51 genes reported with implications in the pathogenesis of breast cancer were screened using next generation sequencing. Germline variations were found in BRCA1, BRCA2, PMS2, p53, and PALB2 genes, previously reported to be associated with MBC as well as FBC. In addition to these, 13 novel missense alterations were detected in eight genes including STK11, FZR1, PALB2, BRCA2, NF2, BAP1, BARD1, and CHEK2. Impact of these missense alterations on structure and function of protein was also analyzed through molecular dynamics simulation. Structural analysis of these single nucleotide polymorphisms (SNPs) revealed significant impact on the encoded protein functioning. © 2019, Springer Science+Business Media, LLC, part of Springer Nature.
Targeting cancer stem cells pathways for the effective treatment of cancer
(Bentham Science Publishers, 2020) Dwivedi, A.R; Thakur, A; Kumar, V; Skvortsova, I; Kumar, V.
Resistance to chemotherapy and relapse are major hurdles for the effective treatment of cancer. Major reason for this is a small sub population of cancer stem cells (CSCs) and its microenvironment. CSCs are critical driving force for several types of cancer, such as gastric, colon, breast and many more. Hence, for the complete eradication of cancer, it is necessary to develop therapeutic approaches that can specifically target CSCs. Chemical agents that target different proteins involved in CSC signaling pathways, either as single agent or simultaneously targeting two or more proteins have generated promising pre-clinical and clinical results. In the current review article, we have discussed various targets and cellular pathways that can be explored for the effective and complete eradication of CSCs. Some latest developments in the field of design, synthesis and screening of ligands to target cancer stem cells have been summarized in the current review article. � 2020 Bentham Science Publishers.